(Total Views: 291)
Posted On: 09/14/2018 1:32:09 PM
Post# of 87162
The DEA actually says they have no choice but to reclassify, only that one quote I highlighted below is of importance for us UNVC shareholders:
https://www.businessinsider.com/cost-first-fd...K&IR=T
Currently, CBD is scheduled alongside marijuana as a schedule 1 drug with "no currently accepted medical use." Beginning on June 25 when Epidiolex was approved, the agency had 90 days to reschedule or reclassify it as a schedule 2, 3, 4, or 5 substance.
"We don't have a choice on that," DEA public affairs officer Barbara Carreno told Business Insider in June. "It absolutely has to become Schedule 2, 3, 4, or 5."
https://www.businessinsider.com/cost-first-fd...K&IR=T
Currently, CBD is scheduled alongside marijuana as a schedule 1 drug with "no currently accepted medical use." Beginning on June 25 when Epidiolex was approved, the agency had 90 days to reschedule or reclassify it as a schedule 2, 3, 4, or 5 substance.
"We don't have a choice on that," DEA public affairs officer Barbara Carreno told Business Insider in June. "It absolutely has to become Schedule 2, 3, 4, or 5."
(2)
(0)
